Related Experiment Videos

Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro

Tamami Okamoto1, Sho-ichi Yamagishi, Yosuke Inagaki

  • 1Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, Japan.

Insights

Incadronate disodium inhibits advanced glycation end product (AGE)-induced angiogenesis by blocking the VEGF pathway in endothelial cells. This suggests potential for treating diabetic retinopathy.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • Advanced glycation end products (AGE) accelerate in diabetes, promoting angiogenesis via vascular endothelial growth factor (VEGF).
  • Proliferative diabetic retinopathy involves aberrant angiogenesis.

Purpose of the Study:

  • To investigate the anti-angiogenic effects of incadronate disodium on AGE-induced responses in vitro.
  • To elucidate the molecular mechanisms underlying incadronate disodium's action.

Main Methods:

  • In vitro assessment of DNA synthesis and tube formation in human microvascular endothelial cells (EC).
  • Analysis of nuclear factor-kappaB (NF-kB) and activator protein-1 (AP-1) transcriptional activation.
  • Investigation of VEGF mRNA levels and the role of protein prenylation (farnesyl pyrophosphate and geranylgeranyl pyrophosphate).

Main Results:

  • Incadronate disodium completely inhibited AGE-induced DNA synthesis and EC tube formation.
  • It prevented transcriptional activation of NF-kB and AP-1, reducing VEGF mRNA upregulation.
  • Farnesyl pyrophosphate, but not geranylgeranyl pyrophosphate, restored the anti-angiogenic effect.

Conclusions:

  • Incadronate disodium blocks the AGE-signaling pathway in microvascular EC by inhibiting protein farnesylation.
  • This drug shows promise as a therapeutic agent for proliferative diabetic retinopathy.

Related Concept Videos